Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The invention relates to 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo [d] imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy)-3,4-dihydro-1,8-naphthyridin-2 (1H)-one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.

The invention relates to 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo [d] imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy)-3,4-dihydro-1,8-naphthyridin-2 (1H)-one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.

The present application relates to the crystalline form of the mesylate salt, the crystalline form of the hydrochloride salt and the crystalline form of the maleate salt of a compound of formula (I):

##STR00001##

The present application also relates to a method for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation using the crystalline forms. The present application also relates to synthetic routes for the compound of formula (I).

The present application relates to the crystalline form of the mesylate salt, the crystalline form of the hydrochloride salt and the crystalline form of the maleate salt of a compound of formula (I):

##STR00001##

The present application also relates to a method for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation using the crystalline forms. The present application also relates to synthetic routes for the compound of formula (I).

The present invention relates to a vanadium and phosphorus mixed oxide (VPO) catalyst for the partial oxidation of n-butane to maleic anhydride. comprising vanadyl pyrophosphate as main component and at least one first promoter element selected from cobalt, iron, copper and mixtures thereof. The present invention further relates to a process for the production of maleic anhydride by partial oxidation of n-butane in the presence of the above mentioned catalyst.

The present invention relates to a vanadium and phosphorus mixed oxide (VPO) catalyst for the partial oxidation of n-butane to maleic anhydride. comprising vanadyl pyrophosphate as main component and at least one first promoter element selected from cobalt, iron, copper and mixtures thereof. The present invention further relates to a process for the production of maleic anhydride by partial oxidation of n-butane in the presence of the above mentioned catalyst.

The invention is directed to a process for the preparation of maleic acid or a derivative thereof. Said process comprising an electrochemical oxidation of a furoic acid compound into maleic acid in an electrolyte solution; and optionally further comprising a step of reacting the maleic acid to the derivative thereof. In an alternative embodiment, said process comprising a first step comprising an electrochemical oxidation in an electrolyte solution of a furanic compound into one or more intermediates; followed by a second step comprising a chemo-catalytic oxidation of said intermediates to provide maleic acid or a derivative thereof.